16 completed, 2 terminated, 1 unknown, 1 withdrawn. 6 Not applicable, 6 Phase 1, 6 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 6 |
| Phase 1 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Stage IIIB Skin Melanoma: new trials by email Literature Review of Stage IIIB Skin Melanoma trials Research Report on Stage IIIB Skin Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Phase 2 | Completed | Emory University | 15 | 2019-06-05 | 2026-10-02 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 10 | 2017-03-21 | 2023-08-03 |
| Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma Internet-Based Intervention, Questionnaire Administration, Survey Administration - Stage 0 Skin Melanoma, Stage I Skin Melanoma | Not applicable | Completed | Rutgers, The State University of New Jersey | 485 | 2017-01-13 | 2026-01-14 |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Imatinib Mesylate, Laboratory Biomarker Analysis, Pembrolizumab - Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma | Phase 1 / Phase 2 | Withdrawn | Joanne Jeter | 2016-11-04 | 2018-04-05 | |
| Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Stage IB Skin Melanoma, Stage IIA Skin Melanoma | Not applicable | Completed | Roswell Park Cancer Institute | 20 | 2016-11-03 | 2022-08-01 |
| MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis - Stage IIA Skin Melanoma, Stage IIB Skin Melanoma | Early Phase 1 | Completed | Mayo Clinic | 23 | 2015-01-27 | 2020-01-14 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Epacadostat, MELITAC 12.1 Peptide Vaccine - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-09-13 | 2018-06-08 |
| Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Not applicable | Completed | Roswell Park Cancer Institute | 10 | 2013-09-04 | 2020-08-07 |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2013-03-26 | 2022-07-22 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Recombinant Interferon Alfa-2b in Treating Patients With Melanoma recombinant interferon alfa-2b, laboratory biomarker analysis - Stage IA Skin Melanoma, Stage IB Skin Melanoma | Not applicable | Completed | William Carson | 34 | 2008-04-22 | 2018-11-02 |
| Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-01-01 | 2017-06-09 |
| A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma CB-10-01 (Transgenic Lymphocyte Immunization) - Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma | Phase 2 | Unknown | Cosmo Bioscience | 20 | 2007-06-01 | 2012-02-13 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Mucosal Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 823 | 2005-06-01 | 2015-10-19 |
| Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2002-10-01 | 2015-01-26 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Aldesleukin, gp100 Antigen, Montanide ISA 51 VG - Recurrent Melanoma, Stage IIIA Skin Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 185 | 1999-12-01 | 2017-11-20 |
Melanoma (20) · Breast Neoplasms (4) · Carcinoma, Renal Cell (4) · Carcinoma, Non-Small-Cell Lung (3) · Ovarian Neoplasms (3) · Urinary Bladder Neoplasms (3) · Astrocytoma (2) · Brain Neoplasms (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Glioblastoma (2) · Lung Neoplasms (2) · Oligodendroglioma (2) · Pancreatic Neoplasms (2)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neuroendocrine Tumors (20) · Nevi and Melanomas (20) · Skin Diseases (20) · Skin Neoplasms (20) · Skin and Connective Tissue Diseases (20) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Lung Diseases (5) · Male Urogenital Diseases (5)
pembrolizumab (3) · Fluorescein (2) · Nivolumab (2) · Sirolimus (2) · aldesleukin (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bevacizumab (1) · Carboplatin (1) · Cognitive Behavioral Therapy (1) · Disulfides (1) · Fluoresceins (1) · Imatinib Mesylate (1) · Immunoglobulin G (1) · Interleukin-2 (1) · Introns (1)
National Cancer Institute (NCI) (5) · Roswell Park Cancer Institute (4) · Rutgers, The State University of New Jersey (4) · Cosmo Bioscience (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Joanne Jeter (1) · Mayo Clinic (1) · Stanford University (1) · William Carson (1)
United States (18) · Australia (1) · Canada (1)
Craig Slingluff (2) · Joseph Skitzki (2) · Adam Berger, MD (1) · Biren Saraiya (1) · Douglas Schwartzentruber (1) · Elliot Coups (1) · Gregory Daniels, MD, PhD (1) · Joanne Jeter, MD (1) · John Kane (1) · Kavita Dhodapkar, MD (1) · Keith Flaherty (1) · Kunle Odunsi (1) · Manali Patel (1) · Matthew Block (1) · Sebastien Hotte (1)
PMID 21631324, PMID 23248256, PMID 23620404, PMID 24047116, PMID 31255801, PMID 32752904, PMID 33955240, PMID 34749008, PMID 35771552, PMID 35780243, PMID 36845705, PMID 39462179, PMID 40132910, PMID 42640721
P30CA072720 (3), P30CA016056 (2), P30CA015083 (1), P30CA016058 (1), P30CA044579 (1), R01CA158318 (1), R01CA171666 (1), R21CA099265 (1), R21CA128367 (1), U01CA132123 (1), U01CA154967 (1), U10CA021115 (1), U10CA180820 (1)